Insmed stock soars on positive Phase 2b study results

Published 10/06/2025, 14:44
© Reuters.

Investing.com -- Shares of Insmed Incorporated (NASDAQ:INSM) surged 27% following the announcement of positive topline results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The company reported that the study met its primary and all secondary efficacy endpoints, leading to investor optimism about the drug’s potential.

The Bridgewater, New Jersey-based biopharmaceutical company disclosed that the study achieved a statistically significant 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance, the primary endpoint. Secondary endpoints also showed favorable outcomes, including a 35.5-meter placebo-adjusted improvement in six-minute walk distance and a 60% placebo-adjusted reduction from baseline in NT-proBNP concentrations, both of which are indicators of the drug’s effectiveness.

Insmed’s announcement also highlighted the tolerability of TPIP, with 75% of patients reaching the highest dose in the study without significant issues. The company plans to engage with the FDA to inform Phase 3 trial design, with studies expected to begin before the end of 2025 for PH-ILD and in early 2026 for PAH.

The promising results from the Phase 2b study not only demonstrate TPIP’s potential as a once-daily therapy but also suggest its capability to become a preferred prostanoid treatment for PAH. Insmed’s commitment to advancing this treatment is evident as they prepare for the next stages of clinical trials.

The positive reaction in Insmed’s stock price reflects the market’s confidence in the company’s pipeline and its ability to bring new therapies to market. Investors will likely keep a close watch on Insmed as it progresses with its Phase 3 trials and further engages with regulatory authorities.

Following the release, competitors Liquidia Technologies (NASDAQ:LQDA) and United Therapeutics (NASDAQ:UTHR) Corporation fell 23.6% and 11.7%, respectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.